ABSTRACT
Clinico-roentgenologic and bacteriologic efficacy and safety of rifapex (rifapentin) were investigated in the complex therapy of 90 patients with newly recorded drug-susceptible tuberculosis. Pifapex was shown to be effective in the treatment of the patients during the acute phase of the disease, during the treatment completeness and during the short preoperative period.
Subject(s)
Antitubercular Agents/therapeutic use , Rifampin/analogs & derivatives , Tuberculosis, Pulmonary/drug therapy , Adult , Antitubercular Agents/administration & dosage , Antitubercular Agents/adverse effects , Antitubercular Agents/pharmacokinetics , Drug Administration Schedule , Drug Resistance, Multiple, Bacterial/drug effects , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Radiography , Rifampin/administration & dosage , Rifampin/adverse effects , Rifampin/pharmacokinetics , Rifampin/therapeutic use , Treatment Outcome , Tuberculosis, Pulmonary/diagnostic imagingSubject(s)
Antibiotics, Antitubercular/therapeutic use , Cycloserine/therapeutic use , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Pulmonary/drug therapy , Adolescent , Adult , Antibiotics, Antitubercular/administration & dosage , Antibiotics, Antitubercular/adverse effects , Cycloserine/administration & dosage , Cycloserine/adverse effects , Female , Humans , Male , Middle Aged , Treatment Outcome , Young AdultSubject(s)
Antitubercular Agents/therapeutic use , Fluoroquinolones/therapeutic use , Mycobacterium tuberculosis , Ofloxacin/therapeutic use , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Pulmonary/drug therapy , Adult , Antitubercular Agents/adverse effects , Antitubercular Agents/pharmacology , Arthralgia/chemically induced , Diarrhea/chemically induced , Drug Resistance, Multiple, Bacterial , Drug Therapy, Combination , Female , Fever/chemically induced , Fluoroquinolones/adverse effects , Fluoroquinolones/pharmacology , Hepatitis/etiology , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/isolation & purification , Nausea/chemically induced , Ofloxacin/adverse effects , Ofloxacin/pharmacology , Sputum/microbiology , Treatment Outcome , Young AdultSubject(s)
Antitubercular Agents/therapeutic use , Mycobacterium tuberculosis/drug effects , Tuberculosis/drug therapy , Adolescent , Adult , Antitubercular Agents/pharmacology , Clinical Trials as Topic , Drug Resistance, Multiple, Bacterial/genetics , Drug Therapy, Combination , Humans , Microbial Sensitivity Tests , Middle Aged , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Oligopeptides/pharmacology , Practice Guidelines as Topic , Tuberculosis/microbiologyABSTRACT
Levofloxacin in vitro demonstrated bactericidal effect against susceptible and multi-drug resistant Mycobacterium tuberculosis: range of MICs was 0.25-0.5 mcg/mL, MBC-0.5-1.0 mcg/mL. Postantibiotic effect after 24-hour exposition to bactericidal concentrations was 35-39 days. Levofloxacin possesed low toxicity when tested in mice lungs tissue culture--maximum safety concentration was 50 mcg/mL. Bactericidal effect of levofloxacin started three days after exposition and was maximal by 7 days of incubation: by this time mycobacterial microcolonies destruction started with detritus formation. It is emphasized that lung cells kept their viability completely. Combination of levofloxacin with isoniazide or pirazinamide resulted in strong synergistic effect obvious after 5 days of incubation, mycobacterial colonies destruction was registered by 7th day. Combination of levofloxacin with rifampicin resulted in antagonistic effect obvious by 7th day of the contact: the resulting effect was statistically significant and was manifested as microcolonies number and size enlargement when compared to data for single levofloxacin.
